ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Vor Biopharma (VOR)
Vor Biopharma stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$19.54▲ +6.60%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Vor Biopharma in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Vor Biopharma
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Vor Biopharma a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $17.24 and $21.62; in 9 out of 10, between $14.10 and $26.42. Estimated annual volatility is 56%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $1.0B
- P/E ratio
- 1.6
- 52-week high
- $28.66
- 52-week low
- $6.50
- Revenue (12 months)
- $0.0M
- Return on equity
- 423.6%
- Free cash flow (12 months)
- $-79.5M
- Beta
- 1.72
What this means
ATLAS does not publish a fair value for VOR right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks VOR has traded between $6.50 and $28.66. Today it is 31.8% below that high and 201% above its low.
Its beta is 1.72: it tends to move more than the market, both up and down.
About the company
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its lead program is telitacicept, a dual-target fusion protein designed to regulate abnormal B-cell activity that drives autoantibody-mediated conditions.
Want to see everything about Vor Biopharma?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Vor Biopharma do?
Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its lead program is telitacicept, a dual-target fusion protein designed to regulate abnormal B-cell activity that drives autoantibody-mediated conditions.
What is the chance VOR goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, VOR ends the month between $17.24 and $21.62.
How big is Vor Biopharma and what is its P/E ratio?
Vor Biopharma's market capitalization is $1.0B. Its price-to-earnings (P/E) ratio is 1.6: you pay $1.6 for each $1 of yearly earnings.
How volatile is VOR?
ATLAS estimates annual volatility at 56%. In a typical month, half of the outcomes end between $17.24 and $21.62.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer